Skip to main content

First Tracks Biotherapeutics, Inc 8-K, filed Nov 3, 2026

First Tracks Biotherapeutics, Inc. (TRAX)

8-K 2026-11-03 For: 2026-11-03
View Original
Added on November 03, 2026

About this 8-K

First Tracks Biotherapeutics, Inc filed this 8-K on November 3, 2026.

First Tracks Biotherapeutics said ANB033 achieved statistically significant protection against gluten-induced intestinal damage and symptoms in a celiac disease Phase 1b cohort. It also completed a $200 million private placement, resulting in $343 million pro forma cash. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits